Prospect Venture Partners
Venture capitalMenlo Park Β· SeedβLate Stage Β· 3 people tracked
Investment thesis
Prospect Venture Partners focuses on biomedical innovation, supporting entrepreneurs pursuing growth opportunities across health care, biotechnology, and medical devices. The firm partners closely with management teams to help build strong companies, drawing on a track record established since its founding in 1997.
Source: firm website, verified Aug 3, 2026.
Team Β· 3 people
from the firm's website & public directoriesWhat they invest in
from 9 of 27 portfolio companiesBiotech Γ7Healthtech Γ6Medical Devices Γ3Consumer Γ1Digital Health Γ1New Materials Γ1
HQs:United StatesΓ7SwitzerlandΓ1
Investments Β· 27 tracked
founders shown can be your intro pathBy year:2016 Β· 12015 Β· 23 dated
Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.
BiotechDigital HealthHealthtechMedical Devices
Amicus is a wholly owned subsidiary of BioMarin Pharmaceutical Inc., a global rare disease biotechnology company that develops medicines for people with genetically defined conditions.
BiotechHealthtechCranbury, US
Daphne Quimi(Executive Officer)Craig A. Wheeler(Director)Ted W. Love(Director)John Crowley(Executive Officer, Director)William D. Baird, III(Executive Officer)Margaret G. McGlynn(Director)
Acquired by Bristol Myers Squibb
PartnerRussell HirschΒ· led
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
HealthtechMountain View, US
William Sutton(Executive Officer)Christopher P. Lowe(Executive Officer, Director)Cary Vance(Executive Officer, Director)Robert Cathcart(Executive Officer)Brian Sheahan(Executive Officer)Joseph Guido(Executive Officer)
PartnerRussell HirschΒ· led
Seattle-based developer of software for managed care.
BiotechSan Diego, US
Steven J. Mento, Ph.D.(Director)David F. Hale(Executive Officer, Director)
BoardPaul Klingenstein(Director)Louis Lacasse(Director)James Scopa(Director)Shahzad Malik(Director)
Jazz Pharmaceuticals is a biopharmaceutical company developing treatments for rare diseases and cancers, with a focus on oncology and biomarker-driven therapies such as those targeting HER2-expressing cancers.
BiotechHealthtech
Acquired by Takeda Pharmaceutical
PartnerRussell HirschΒ· led
BiotechSouth San Francisco, US
Jin-Long Chen(Executive Officer, Director)David V. Goeddel(Director)William J. Rieflin(Executive Officer, Director)
BoardPeter Svennilson(Director)Mark Leschly(Director)David Schnell(Director)
Pharmaceutical company acquired by Alexion in 2020.
PartnerRussell HirschΒ· led
AtriCure develops medical devices and solutions for atrial fibrillation (Afib) treatment, focusing on patient care and early recognition of cardiac health changes.
BiotechMedical DevicesRedwood City, US
Victor Tong(Director)Russell Seiber(Executive Officer, Director)Theodore Huber(Director)Pam Simons(Executive Officer)Greg Fung(Executive Officer)Steven Hochberg(Director)
PartnerRussell HirschΒ· led
Acquired by Valeant via Medicis
Acquired by Emergent BioSolutions
Exits Β· 6
IPOs and acquisitions across the tracked portfolioInsmedNASDAQ: INSMAmira Pharmaceuticalsacq. by Bristol Myers SquibbMillennium Pharmaceuticalsacq. by Takeda PharmaceuticalPortola Pharmaceuticalsacq. by AlexionTopica Pharmaceuticalsacq. by MedicisTrubionacq. by Emergent Biosolutions
Portfolio news
latest coverage across their companiesInsmed Β· geekwire.com Β· Jul 13, 2026
Frequently asked questions
- What stage does Prospect Venture Partners invest at?
- Prospect Venture Partners invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Prospect Venture Partners's typical check size?
- Prospect Venture Partners typically writes checks of $3M β $5M.
- What sectors does Prospect Venture Partners focus on?
- Prospect Venture Partners focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
- Where is Prospect Venture Partners located?
- Prospect Venture Partners is headquartered in Menlo Park, US.
- Does Prospect Venture Partners lead rounds?
- Yes, Prospect Venture Partners leads investment rounds.
Similar investors
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
Khosla Ventures is a venture capital firm known for backing bold, contrarian bets in world-class teams that can reshape entire industries.
NJF Capital is the venture investment arm of NJF Holdings, the private investment group founded by Nicole Junkermann. It invests internationally in transformative technology companies.
Panacea Venture is a global investment firm, spun out from Kleiner Perkins, focused on life sciences and healthcare innovation. It invests across geographies and stages, from company formation through expansion and public markets.